Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma

Author(s): Lucas V. dos Santos, Andre L. Carvalho

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 6 , Issue 1 , 2011

Become EABM
Become Reviewer
Call for Editor


Despite recent advances in treatment of head and neck cancer, survival has not improved as expected. Bcl-2 family proteins play important role in regulating apoptosis. Recently, newer molecules have been developed for inhibition of Bcl-2 related proteins. We, herein aim to discuss the importance of Bcl-2 family proteins to the development of head and neck cancer and how the targeted-therapy for inhibition of Bcl-2 and related proteins, based on new drugs and recent patents, could improve the efficacy of the systemic therapy.

Keywords: Anticancer drugs, apoptosis, Bcl-2 family proteins, head and neck cancer, patents, targeted-therapy, squamous cell carcinoma, HNSCC, human papillomavirus (HPV) infection, radiochemotherapy, EGFR, FADD, tumorigenesis, Bcl-xL, Mcl-1, BH3-only, Bim, Puma, STAT3, fluoropyrimidines, VEGF, angiogenesis, TERT, Bortezomib, Human papillo-mavirus proteins, Azadirachta indica, gefitinib, Epigallocatechin-3 gallate, EGCG, Apogossypolone, Streptomyces, Chelidonium majus, obatoclax, BIE, BBF

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [45 - 57]
Pages: 13
DOI: 10.2174/157489211793980042

Article Metrics

PDF: 24